# Stem cells weekly evidence review - October 19, 2026 Decision: substantive public update warranted. Add controlled clinical evidence, a new European regulatory opinion and a registry follow-up. No general cure claim, dosing guidance or clinic recommendation. Access date: 2026-10-19 PDT, checked with system clock. Previous review: October 12. Literature entry-date and trial-update window: October 13-19 inclusive. Some newly indexed papers were published earlier; those are identified as catch-up, not misrepresented as this week's discoveries. This is targeted monitoring, not a systematic review or exhaustive international regulatory audit. Article: https://managingexpectations.net/blog/articles/stem-cells-evidence-costs-risks-global-guide.html Previous note: https://managingexpectations.net/research/health/stem-cells-weekly-update-2026-10-12.md ## Selected findings: claim-to-source trail ### 1. Parkinson's randomized trial: primary efficacy endpoint not met Kangwen Peng et al. "Intranasal human neural stem cell therapy in early-onset Parkinson's disease with motor complications: A randomized, double-blind, placebo-controlled trial." Cell Transplantation. DOI: 10.1177/09636897261494929. PMID 42868224. https://pubmed.ncbi.nlm.nih.gov/42868224/ NCBI EFetch XML verified the abstract, publication date and conflict disclosure. Electronic ArticleDate is October 13, 2026. A web-extractor representation labelled the item October 1; NCBI XML is used for bibliographic dating, and the public article simply says newly indexed. Twenty-four participants randomized 2:1; 12-month follow-up. Primary outcome: change in MDS-UPDRS Part IV at six months. Key passage: "No significant difference was observed in the primary endpoint" (least-squares mean difference 0.42; 95% CI -4.29 to 5.13; P=0.853). Exploratory limb-motor and PET findings are hypothesis-generating, not a replacement for a missed primary endpoint. The abstract reports 137 adverse events and six serious adverse events overall, without group-specific counts or causal attribution. Do not say six treatment-caused serious injuries or declare the product safe. Abstract-level appraisal; full methods/adverse-event tables not independently audited. Disclosed interests: grants from Shanghai Angecon Biotechnology and named authors employed by the company. Product is ANGE-S003 neural stem cells; it is not REPOSE's adipose-derived product, STEM-PD's surgically placed dopaminergic progenitors, or Japan's AMCHEPRY. Evidence label: under study; primary efficacy endpoint not met. No recommendation to administer cells intranasally or otherwise. ### 2. Stress urinary incontinence: response rates versus comparative efficacy Shadha Nasser Bahutair et al. "Post-Treatment Response and Safety of Stem Cell-Based Urethral Injection Therapy for Female Stress Urinary Incontinence: A Systematic Review and Meta-Analysis." Journal of Clinical Medicine, October 8, 2026. DOI: 10.3390/jcm15197737. PMID 42882197. https://pubmed.ncbi.nlm.nih.gov/42882197/ NCBI XML and abstract checked. Newly captured this week, but publication predates the prior review. Includes 21 studies/885 women. Seventeen studies contributed to pooled post-treatment response (63.7%); this is NOT a treatment-attributable success probability. Two placebo-controlled trials with a common 12-month endpoint showed no significant comparative advantage (RR 1.02, 95% CI 0.85-1.23, P=0.85). Endpoint was at least 50% reduction in stress-incontinence episode frequency. Different outcomes/designs and heterogeneity limit pooled interpretation. No significant difference does not establish equivalence or rule out all benefit. Safety reporting mostly describes minor/transient events and does not establish long-term or rare-event safety. Key passage: "this estimate cannot be interpreted as treatment-specific efficacy." Review-level/abstract-level appraisal, not a re-analysis of each trial. Evidence label: investigational; controlled evidence insufficient for an efficacy upgrade. ### 3. EMA negative opinion after re-examination: Yartemlea Official October meeting report, published October 16: https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2026 Official medicine page / questions and answers: https://www.ema.europa.eu/en/medicines/human/EPAR/yartemlea Both retrieved directly, HTTP 200; full extracted medicine-page text retained locally. Opinion after re-examination: October 15, 2026; initial opinion: June 25. Q&A reference EMA/228620/2026, first published October 16. A stale footer last-updated date on the medicine page does not override the dated opinion and matching meeting report. Narsoplimab is a monoclonal antibody intended for high-risk HSCT-associated thrombotic microangiopathy, not a stem-cell product. Proposed population: adults and children from two years. EMA describes a main study of 28 adults without a concurrent comparator, concurrent medications, study-conduct/endpoint concerns, unreliable external comparisons and insufficient pediatric evidence. It concluded that benefits and risks could not be established and that the unresolved efficacy concerns also prevented conditional marketing authorization. Key passage: "The Agency concluded that the concerns raised after the initial assessment were still unresolved." Status: CHMP/EMA negative opinion, not a newly verified European Commission decision. Do not call it a global ban, failure of HSCT itself, or proof of zero drug activity. EMA's page separately notes U.S. authorization; no U.S. approval details are added without the FDA product record. Update the report's Europe row with the narrow EU development. ### 4. COPD follow-up: new U.S. registry record https://clinicaltrials.gov/study/NCT07871890 https://clinicaltrials.gov/api/v2/studies/NCT07871890 Record obtained in the official ClinicalTrials.gov v2 search response. First posted and last update posted October 13, 2026. Sponsor SMSbiotech; SORT-COPD II, phase 1b/2a, open-label, non-randomized, planned 125 participants, U.S. site listed at University of Miami. Status NOT_YET_RECRUITING; hasResults=false. Estimated October 1 start is not evidence treatment began and does not override the explicit status. Sponsor describes a sequential safety cohort then expansion; no untreated concurrent control is listed. This adds a traceable study record to September's company announcement. A sponsor-submitted entry is not independent authentication of IND correspondence, FDA marketing approval, efficacy or a demonstrated lung-regeneration outcome. No recruitment invitation or dosing instructions published. Evidence label: registered investigational study, no outcomes yet. ## Required source checks and unchanged conclusions ### FDA - Approved cellular/gene therapy list: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products - Consumer safety page: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies - Safety index: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/2026-safety-and-availability-communications Direct requests were blocked through an abuse-detection apology page; web extraction recovered content. Approved-list extraction includes Tregzi and Omisirge, date September 17, but is visibly abbreviated: not a complete product-by-product audit. Safety-index extraction was also partial. No newly verified weekly stem-cell authorization or warning is inferred from this partial coverage. Consumer page is dated June 3, 2021 and reiterates serious risks and that registration is not approval. Its historic approved-product inventory must not be presented as a current comprehensive list. Existing narrow-indication and unapproved-product cautions remain. Searches also surfaced the October 14 renewal of the Cellular, Tissue, and Gene Therapies Advisory Committee. Administrative renewal is not a therapeutic approval; not selected for the clinical report. ### Health Canada - https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/cell-therapy-policy.html - https://recalls-rappels.canada.ca/en/alert-recall/health-canada-advising-canadians-about-potential-health-risks-associated-unauthorized Both directly retrieved (200); official-site search also checked for newer alerts. Advisory is May 15, 2019; historical product counts are not current inventories. Autologous origin does not establish safety or exemption. No relevant new Canadian cell-therapy policy/advisory was verified for this review window. Search surfaced older access/funding reporting and regulatory-modernization advocacy, not a new product authorization. No Canadian approval or funding conclusion added. ### NIH/NCI and trial registries - https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant - https://clinicaltrials.gov/study/NCT05316701 - https://clinicaltrials.gov/study/NCT06986070 NCI direct retrieval: established specialist transplantation remains distinct from broad regenerative claims. Precision-T registry last update remains March 4, results available; this is not a new October result. Australian SORT-COPD remains phase 1, recruiting, estimated 18 participants, no posted results, last updated August 11. A broader registry query screened last-update dates October 13-19 for stem cell/mesenchymal/iPSC/exosome terms. Both pages retrieved: 196 records, 196 unique NCT identifiers. Broad matches include drugs and studies mentioning transplantation in eligibility, not just cell interventions. Updated iPSC retinal, ALS/MSC/exosome, autoimmune and transplant records are leads; a posting date is not proof of new clinical outcomes. Four records show results available, including non-cell drugs; not interpreted as four new successful stem-cell trials. The relevant new COPD record is detailed above. ### ISSCR and AAOS - https://www.isscr.org/guidelines - https://www.isscr.org/isscr-news - https://www.isscr.org/stem-cell-policy - https://www.orthoinfo.org/treatment/use-of-stem-cells-in-orthopaedics Guidelines/news/AAOS retrieved directly. ISSCR policy direct URL returned 404; web extraction recovered policy text. Guidelines still identify August 2025 version 1.2, with targeted embryo-model changes and other sections from 2021. Direct news page contains October 14 meeting notices and October 15 mouse nicotine/hematopoietic research, not new human treatment evidence. Its manufacturing directory is a professional resource, not a clinical endorsement. Direct news retrieval was more current than the web-extracted version; retained the direct snapshot. AAOS continues to describe insufficient/mixed orthopedic efficacy evidence. No arthritis cure or cartilage-regeneration upgrade. ### Global policy and medical tourism - EU: EMA meeting and Yartemlea record above are the substantive regulatory finding. - UK MHRA: https://www.gov.uk/guidance/advanced-therapy-medicinal-products-regulation-and-licensing-in-uk Direct 200; last updated September 11, 2026, adding British Pharmacopoeia information. No weekly change established. - Japan PMDA: https://www.pmda.go.jp/english/review-services/reviews/approved-information/0004.html Direct 200; selected English review index retains AMCHEPRY/RiHEART March entries. This translated index is selective, not a comprehensive current approval/safety audit. Existing conditional-approval wording retained. - Singapore HSA: https://www.hsa.gov.sg/ctgtp/overview/regulatory-overview/ Direct 403; extraction recovered full framework, last updated April 14. Culture-expanded cells fall into higher-risk Class 2. No new weekly rule change verified. - Australia TGA: https://www.tga.gov.au/news/news-articles/stem-cell-treatments-and-regulation-quick-guide-consumers Direct timeout; extraction recovered consumer safety guidance. Historic guidance, not a current complete approvals inventory. No new weekly policy change verified. - Mexico/Panama/Cayman: broad and dated searches retried after an empty result. Follow-up results were mostly irrelevant or clinic/medical-tourism marketing. No new regulator action, independently verified adverse-event cluster, comparable price change or newsworthy patient outcome was established. This is a coverage limitation, not certification that no local developments occurred. No clinic endorsed; no advertising price used to revise the report. No new credible public testimony selected. Testimonials remain anecdotal, even when sincerely reported. ## Literature screen and non-selected leads NCBI ESearch/EFetch queried stem cells, MSCs, iPSCs, exosomes and hematopoietic transplantation with trial/safety/adverse-event/Parkinson's/diabetes/spinal-cord/arthritis/autoimmune/cancer terms; entry dates October 13-19. Search returned 328 records, all identifiers retrieved. Title/abstract filtering and targeted clinical appraisal were performed; not all full texts were read. PubMed indexing is not endorsement, and entry dates differ from publication dates. The two selected clinical abstracts and official regulatory/registry material justify a public change without promoting uncontrolled signals. Additional leads retained, not elevated into treatment recommendations: - PMID 42870948, DOI 10.3389/fmed.2026.1945865, published September 29: ten-person uncontrolled hEDS exosome-rich MSC-secretome pilot, custom symptom instrument, one extended-treatment responder. Reported remission in one person is not cure evidence. Other initial responders reportedly returned to baseline after stopping. One author affiliation is Direct Biologics; NCBI conflict statement declares no relevant commercial/financial relationships. That disclosure/affiliation needs fuller appraisal before any featured coverage. Primary page opened: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1945865/full - PMID 42893874: 20 young sickle-cell HSCT recipients with cardiac imaging follow-up and age-matched disease-modifying-treatment comparison; promising disease-specific observational outcomes, not a randomized universal heart-repair result. - PMID 42890131: meta-analysis of 11 ulcer trials/474 participants reports improved healing but heterogeneity and limited samples; does not establish regulatory approval or absence of rare harms. - PMID 42864656: OPTIMIZE, 21 participants before early termination, improved collection efficiency with a mobilizing drug; not evidence of superior engraftment or overall survival. - Diabetes/islet, spinal-cord/exosome, autoimmune and cancer searches include cell/animal models and reviews. Do not translate laboratory regeneration into human efficacy. New USC immune-progenitor reporting describes mouse cancer experiments, not an available human cancer cure. - DOI 10.1038/s41591-026-04525-0 (STEM-PD) surfaced in current searches but publisher metadata confirms July 9 publication, with September issue placement. Direct full text retrieved. Not described as an October publication. Its eight-person uncontrolled safety cohort also requires whole-procedure risk framing, including a fatal infection during immunosuppression, rather than focusing only on events attributed to the cell product. ## What changed, what did not, and deployment scope Added a dated October 19 section immediately after the medical caution, with four source-linked findings and evidence labels. Updated article review date and Europe regulatory row. The original deep report and earlier updates remain intact. Article and this note receive October 19 sitemap lastmod values. Health page, assets, stylesheet and pricing remain unchanged: no new report/link was added and no sufficiently comparable current pricing evidence was found. Medical boundaries and narrow-indication distinctions remain unchanged. Local backups: _local-backups/stem-cells-2026-10-19/. Remote pre-change backups: domains/managingexpectations.net/backups/stem-cells-20261019/. DNS and HTTP headers confirmed the existing Hostinger shared target (195.35.15.247, LiteSpeed/Hostinger). No KillerWolf, DNS or server-configuration changes. Deploy only the article, this source note and sitemap to their existing directory-specific Hostinger paths. Remote and live byte/content verification is recorded separately in the local evidence folder; this note alone is not a deployment-success assertion. No browser tool is available, so rendering checks are limited to HTML parsing, relative-link validation, live HTTP/content checks and asset availability. Local audit folder: research/health/stem-cells-weekly-evidence-2026-10-19/ (PubMed XML/query/abstracts, official-page snapshots, registry JSON and retrieval status). Raw registry records contain protocol details and remain local; only this narrative source note is published. Suggested next review: check the COPD registry for actual recruitment/results, inspect full Parkinson's adverse-event tables if accessible, monitor EMA/EC follow-through without conflating opinion with decision, and retain the distinction between post-treatment response and controlled efficacy. Medical boundary: education and source review only; not medical advice, diagnosis, treatment instructions, dosing, clinic endorsement or advice to travel for therapy.